Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: A case report and review of the literature.
Fiche publication
Date publication
décembre 2022
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr AUBIN François, Dr NARDIN Charlée
Tous les auteurs :
Neuville C, Aubin F, Puzenat E, Popescu D, Crepin T, Nardin C
Lien Pubmed
Résumé
Adverse events (AEs) of immune checkpoint inhibitors (ICIs) are frequent and mainly due to an overactivity of the immune system leading to excessive inflammatory responses (immune-related AE) that can affect any organ of the body. Beside the most frequent AEs, there are rare AEs whose diagnosis and treatment can be challenging. We report here a singular case of capillary leak syndrome (CLS) associated with chylothorax occurring in a patient who has been treated with adjuvant nivolumab (anti-PD1) for resected AJCC stage IIB primary melanoma.
Mots clés
VEGF, adverse event, anti-PD1, capillary leak syndrome, chylothorax, immune checkpoint inhibitor
Référence
Front Oncol. 2022 12 12;12:1032844